mifenovir effectiveness in the treatment of COVID-19
Phase 3
- Conditions
- Covid-19.Covid-19U07.1
- Registration Number
- IRCT20200322046833N1
- Lead Sponsor
- Center for Progress and Development of Iran
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Age >18 years old
Patients with a probable and definitive diagnosis of COVID-19 who are candidates for hospitalization and receiving antiviral regimens.
Presence of at least one clinical sign (including fever, chills, cough, myalgia) with positive virologic specimen or imaging findings for COVID-19
Exclusion Criteria
Patient or fellows' dissatisfaction with entering or continuing the study
History or any signs of hypersensitivity to umifenovir
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical improvement includes fever rupture. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, thermometer, questionnaire.;Clinical improvement includes SPO2 >93%. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, pulse oxymetery,questionnaire.;Improvement of respiratory symptoms. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Physical examination, ct scan,questionnaire.;Adverse effects. Timepoint: Since admission to the hospital then daily monitoring. Method of measurement: Questionnaire, physical examination.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization. Timepoint: 7 days to 1 months after beginning the treatment. Method of measurement: Questionnaire.;Clinical outcome. Timepoint: 7 days to 1 months after beginning the treatment. Method of measurement: Questionnaire.;Lipoxin. Timepoint: day-0, day-2, day-4. Method of measurement: measuring the plasma concentration of the biomarker with ELISA kit.;Prostaglandin. Timepoint: day-0, day-2, day-4. Method of measurement: measuring the plasma concentration of the biomarker with ELISA kit.;Leukotriene. Timepoint: day-0, day-2, day-4. Method of measurement: measuring the plasma concentration of the biomarker with ELISA kit.;Resolvin. Timepoint: day-0, day-2, day-4. Method of measurement: measuring the plasma concentration of the biomarker with ELISA kit.